2 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Hypertension, Essential: new trials by email Literature Review of Hypertension, Essential trials Research Report on Hypertension, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SPC1001 in Patients With Essential Hypertension SPC 1001 Mid2, SPC 2002, SPC 2003 - Hypertension, Essential, Cardiovascular Diseases | Phase 2 | Recruiting | Shin Poong Pharmaceutical Co. Ltd. | 252 | 2024-06-12 | 2025-02-14 |
| A Study to Evaluate the Efficacy and Safety of AD-209 AD-209, AD-209-1A, AD-209-1B - Hypertension, Essential | Phase 2 | Completed | Addpharma Inc. | 221 | 2023-04-05 | 2024-04-05 |
| Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg - Hypertension, Essential | Phase 2 | Completed | Bayer | 1381 | 2011-04-01 | 2017-04-18 |
Essential Hypertension (3) · Cardiovascular Diseases (1)
Hypertension (3) · Vascular Diseases (3) · Cardiovascular Diseases (2)
Nifedipine (1) · candesartan cilexetil (1)
Addpharma Inc. (1) · Bayer (1) · Shin Poong Pharmaceutical Co. Ltd. (1)
South Korea (3) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Italy (1) · Lithuania (1) · Russia (1) · South Africa (1) · Spain (1) · Ukraine (1) · United Kingdom (1) · United States (1)
Chang Gyu Park, M.D., Ph.D (1)
2009 (1)